News

The Food and Drug Administration (FDA) recently gave full approval to Leqembi (lecanemab) for patients in the early stages of Alzheimer’s disease. Physicians and researchers at Washington University School of Medicine’s Charles F. and Joanne Knight Alzheimer Disease Research Center (Knight ADRC) in St. Louis were involved in the clinical trials evaluating Leqembi, in which they enrolled […]

The city of St. Louis has the highest rate of Alzheimer’s dementia cases in Missouri, and new evidence from Washington University’s School of Medicine shows that social factors like income, race and education play a role in access to treatment and diagnosis. The new observational study, focused on the Washington University Memory Diagnostic Center, showed […]

Nearly every person with Down syndrome eventually develops Alzheimer’s disease, yet people with the syndrome routinely are excluded from Alzheimer’s clinical trials, as the cognitive assessment tools designed for the general population often are inappropriate for people with developmental disabilities. Consequently, nobody knows whether the new Alzheimer’s therapeutics hitting the market will work for people […]

Patients who live in less affluent neighborhoods and those from underrepresented racial or ethnic groups are less likely than others to receive specialized care for dementia, including Alzheimer’s disease, a new study from Washington University School of Medicine in St. Louis indicates. Further, the research shows that Black people are more likely than white people […]

The Department of Neurology congratulates former Neurology Research Lab Manager Cynthia Hodge for being awarded the Neurology Staff Employee of the Quarter for Q4 FY23. Hodge was nominated by faculty and staff because of her hard work and dedication to her role and the people she manages. Those who nominated her, in particular, highlighted how […]